抗癌药物诱发的间质性肺病(DIILD)越来越受到临床关注,相关指导文件的质量变得至关重要。我们的目的是评估抗癌DIILD文件的质量并总结建议。临床实践指南(CPG)和评估建议的共识声明,治疗,并在电子数据库中搜索了抗癌DIILD的监测,指南组织的网站,和专业社团。文件的质量使用评估指南II(AGREEII)方法进行评估,并对具体建议进行汇总和比较,以分析文档之间的一致性。共有11份文件符合资格,包括6个CPG和5个共识声明。AGREEII评估的质量差异很大,文档域之间和跨域文档之间。范围和目的以及演示文稿清晰度的领域获得了最高的中位数得分,而利益相关者参与领域得分最低。文件之间的建议不一致,特别是关于类固醇方案的选择。指导文件的方法质量需要提高,特别是在利益相关者参与的领域。关于具体评价建议的文件存在不一致之处,治疗和,监测抗癌DIILD,多学科专家之间需要进一步讨论以达成协议。特别是,我们将注意力集中在类固醇治疗方案的差异上,未来仍需研究与激素治疗相关的不良事件的风险,并发现精确的生物标志物.
Anticancer drug-induced interstitial lung disease (DIILD) has received increasing clinical attention, and the quality of relevant guidance documents has become critical. Our purpose was to assess the quality of documents for anticancer DIILD and summarize the recommendations. Clinical practice
guidelines (CPGs) and
consensus statements with recommendations were searched in electronic databases, websites of
guideline organizations, and professional societies. The quality of documents was assessed using the Appraisal of
Guidelines for Research & Evaluation II (AGREE II) methodology, and the specific recommendations were aggregated and compared. A total of 11 documents were eligible, including 6 CPGs and 5
consensus statements, and the quality of AGREE II assessments differed greatly. The domains of scope and purpose and clarity of presentation received the highest median scores, while the stakeholder involvement domain received the lowest score. Recommendations were inconsistent between documents, particularly regarding the selection of steroid regimens. The methodological quality of the guidance documents needs to be enhanced, especially in the domain of stakeholder involvement. Inconsistencies exist in documents, and further discussions among multidisciplinary experts are needed. Particularly, differences in steroid regimens require attentions, and researches on the risks of adverse events and discovery of precise biomarkers are necessary.